167 related articles for article (PubMed ID: 18070954)
21. 1,5-benzodiazepines, a novel class of hepatitis C virus polymerase nonnucleoside inhibitors.
Nyanguile O; Pauwels F; Van den Broeck W; Boutton CW; Quirynen L; Ivens T; van der Helm L; Vandercruyssen G; Mostmans W; Delouvroy F; Dehertogh P; Cummings MD; Bonfanti JF; Simmen KA; Raboisson P
Antimicrob Agents Chemother; 2008 Dec; 52(12):4420-31. PubMed ID: 18852280
[TBL] [Abstract][Full Text] [Related]
22. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.
Tomei L; Altamura S; Bartholomew L; Biroccio A; Ceccacci A; Pacini L; Narjes F; Gennari N; Bisbocci M; Incitti I; Orsatti L; Harper S; Stansfield I; Rowley M; De Francesco R; Migliaccio G
J Virol; 2003 Dec; 77(24):13225-31. PubMed ID: 14645579
[TBL] [Abstract][Full Text] [Related]
23. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor.
Kati W; Koev G; Irvin M; Beyer J; Liu Y; Krishnan P; Reisch T; Mondal R; Wagner R; Molla A; Maring C; Collins C
Antimicrob Agents Chemother; 2015 Mar; 59(3):1505-11. PubMed ID: 25534735
[TBL] [Abstract][Full Text] [Related]
24. Identification of a novel resistance mutation for benzimidazole inhibitors of the HCV RNA-dependent RNA polymerase.
Delang L; Froeyen M; Herdewijn P; Neyts J
Antiviral Res; 2012 Jan; 93(1):30-8. PubMed ID: 22033247
[TBL] [Abstract][Full Text] [Related]
25. Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors.
Yang W; Zhao Y; Fabrycki J; Hou X; Nie X; Sanchez A; Phadke A; Deshpande M; Agarwal A; Huang M
Antimicrob Agents Chemother; 2008 Jun; 52(6):2043-52. PubMed ID: 18411324
[TBL] [Abstract][Full Text] [Related]
26. NMR reveals the intrinsically disordered domain 2 of NS5A protein as an allosteric regulator of the hepatitis C virus RNA polymerase NS5B.
Bessa LM; Launay H; Dujardin M; Cantrelle FX; Lippens G; Landrieu I; Schneider R; Hanoulle X
J Biol Chem; 2017 Nov; 292(44):18024-18043. PubMed ID: 28912275
[TBL] [Abstract][Full Text] [Related]
27. Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothiadiazine inhibitor.
Nguyen TT; Gates AT; Gutshall LL; Johnston VK; Gu B; Duffy KJ; Sarisky RT
Antimicrob Agents Chemother; 2003 Nov; 47(11):3525-30. PubMed ID: 14576112
[TBL] [Abstract][Full Text] [Related]
28. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase.
Ahmed-Belkacem A; Ahnou N; Barbotte L; Wychowski C; Pallier C; Brillet R; Pohl RT; Pawlotsky JM
Gastroenterology; 2010 Mar; 138(3):1112-22. PubMed ID: 19962982
[TBL] [Abstract][Full Text] [Related]
29. Novel nonnucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase.
Howe AY; Bloom J; Baldick CJ; Benetatos CA; Cheng H; Christensen JS; Chunduru SK; Coburn GA; Feld B; Gopalsamy A; Gorczyca WP; Herrmann S; Johann S; Jiang X; Kimberland ML; Krisnamurthy G; Olson M; Orlowski M; Swanberg S; Thompson I; Thorn M; Del Vecchio A; Young DC; van Zeijl M; Ellingboe JW; Upeslacis J; Collett M; Mansour TS; O'Connell JF
Antimicrob Agents Chemother; 2004 Dec; 48(12):4813-21. PubMed ID: 15561861
[TBL] [Abstract][Full Text] [Related]
30. Understanding the drug resistance mechanism of hepatitis C virus NS5B to PF-00868554 due to mutations of the 423 site: a computational study.
Jiao P; Xue W; Shen Y; Jin N; Liu H
Mol Biosyst; 2014 Apr; 10(4):767-77. PubMed ID: 24452008
[TBL] [Abstract][Full Text] [Related]
31. Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
Paeshuyse J; Vliegen I; Coelmont L; Leyssen P; Tabarrini O; Herdewijn P; Mittendorfer H; Easmon J; Cecchetti V; Bartenschlager R; Puerstinger G; Neyts J
Antimicrob Agents Chemother; 2008 Sep; 52(9):3433-7. PubMed ID: 18625766
[TBL] [Abstract][Full Text] [Related]
32. Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro.
Lu L; Dekhtyar T; Masse S; Pithawalla R; Krishnan P; He W; Ng T; Koev G; Stewart K; Larson D; Bosse T; Wagner R; Pilot-Matias T; Mo H; Molla A
Antiviral Res; 2007 Oct; 76(1):93-7. PubMed ID: 17561278
[TBL] [Abstract][Full Text] [Related]
33. Identification and structure-based optimization of novel dihydropyrones as potent HCV RNA polymerase inhibitors.
Li H; Tatlock J; Linton A; Gonzalez J; Borchardt A; Dragovich P; Jewell T; Prins T; Zhou R; Blazel J; Parge H; Love R; Hickey M; Doan C; Shi S; Duggal R; Lewis C; Fuhrman S
Bioorg Med Chem Lett; 2006 Sep; 16(18):4834-8. PubMed ID: 16824756
[TBL] [Abstract][Full Text] [Related]
34. Ligand-induced changes in hepatitis C virus NS5B polymerase structure.
Rigat K; Wang Y; Hudyma TW; Ding M; Zheng X; Gentles RG; Beno BR; Gao M; Roberts SB
Antiviral Res; 2010 Nov; 88(2):197-206. PubMed ID: 20813137
[TBL] [Abstract][Full Text] [Related]
35. 1a/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus.
Nyanguile O; Devogelaere B; Vijgen L; Van den Broeck W; Pauwels F; Cummings MD; De Bondt HL; Vos AM; Berke JM; Lenz O; Vandercruyssen G; Vermeiren K; Mostmans W; Dehertogh P; Delouvroy F; Vendeville S; VanDyck K; Dockx K; Cleiren E; Raboisson P; Simmen KA; Fanning GC
J Virol; 2010 Mar; 84(6):2923-34. PubMed ID: 20071590
[TBL] [Abstract][Full Text] [Related]
36. Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase.
Shih IH; Vliegen I; Peng B; Yang H; Hebner C; Paeshuyse J; Pürstinger G; Fenaux M; Tian Y; Mabery E; Qi X; Bahador G; Paulson M; Lehman LS; Bondy S; Tse W; Reiser H; Lee WA; Schmitz U; Neyts J; Zhong W
Antimicrob Agents Chemother; 2011 Sep; 55(9):4196-203. PubMed ID: 21746939
[TBL] [Abstract][Full Text] [Related]
37. Molecular modeling and residue interaction network studies on the mechanism of binding and resistance of the HCV NS5B polymerase mutants to VX-222 and ANA598.
Xue W; Jiao P; Liu H; Yao X
Antiviral Res; 2014 Apr; 104():40-51. PubMed ID: 24462692
[TBL] [Abstract][Full Text] [Related]
38. Discovery of substituted N-phenylbenzenesulphonamides as a novel class of non-nucleoside hepatitis C virus polymerase inhibitors.
May MM; Brohm D; Harrenga A; Marquardt T; Riedl B; Kreuter J; Zimmermann H; Ruebsamen-Schaeff H; Urban A
Antiviral Res; 2012 Aug; 95(2):182-91. PubMed ID: 22580131
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine.
Lam AM; Espiritu C; Murakami E; Zennou V; Bansal S; Micolochick Steuer HM; Niu C; Keilman M; Bao H; Bourne N; Veselenak RL; Reddy PG; Chang W; Du J; Nagarathnam D; Sofia MJ; Otto MJ; Furman PA
Antimicrob Agents Chemother; 2011 Jun; 55(6):2566-75. PubMed ID: 21444700
[TBL] [Abstract][Full Text] [Related]
40. Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance.
Leumi S; Guo M; Lu J; Wang Z; Gan T; Han L; Ngari J; Tong Y; Xiang X; Xie Q; Wang L; Zhong J
Antiviral Res; 2022 Jan; 197():105224. PubMed ID: 34864126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
